Astellas become first Japanese pharmaceutical branch with KRW 200 billion annual sales
Astellas Pharma Korea(CEO Hae-do Jung) has enter the sales wall of KRW 200 billion for the first time as a Japanese multinational pharmaceutical company branched in the Korean market.
According to the electronic official notice on the 6th, Astellas, a corporate body which balance accounts on Ma...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
